The T2EVOLVE consortium is being coordinated by the Universitätsklinikum Würzburg, Germany and Servier, France. The interdisciplinary T2EVOLVE consortium is made up of 27 European partners from 9 different nations. Partners include university and non-university research facilities, pharmaceutical and biotechnology companies, as well as regulatory authorities and patients and professional associations. A core feature of this approach will be to involve patient stakeholders as contributing members of the team across all levels of the R&D process.
Among partners, also the San Raffaele University:
“San Raffaele University is a cell and gene therapy center in Europe recognized for the excellence of its teaching and research. The University participates in the T2EVOLVE EU project to contribute, with its deep knowledge in the field of cancer immunotherapy, to the goal of accelerating the clinical translation of therapies with engineered T cells. PI of the project is Prof. Chiara Bonini, Full Professor of Hematology and Head of the Experimental Hematology Unit of the San Raffaele Hospital, with the fundamental collaboration of Prof. Fabio Ciceri, Full Professor of Hematology, Scientific Director of the San Raffaele Hospital, Head of the Hematology and Bone Marrow Transplant and Oncohematology Units, of Dr. Monica Casucci, Group leader of the Innovative Immunotherapy Unit, and of Prof. Paolo Dellabona, Director of the Immunology, Transplant and Infectious Diseases Division”.
Further information on the project will be available from February 2021 on the website www.t2evolve.eu